专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180326143A1 DEVICE, SYSTEM, AND METHOD INCLUDING MICRO-PATTERNED CELL TREATMENT ARRAY 审中-公开
公开(公告)号：US20180326143A1
公开(公告)日：2018-11-15
申请号：US16032219
申请日：2018-07-11
申请人： Gearbox LLC
发明人： Roderick A. Hyde , Lowell L. Wood, JR.
IPC分类号： A61M1/36 , C12Q3/00 , G01N33/50 , A61B17/435 , B82Y20/00
CPC分类号： A61M1/3689 , A61B17/435 , B82Y20/00 , C12Q3/00 , G01N33/505 , G01N33/5091 , Y10T436/115831
摘要： Devices, systems, or methods are disclosed herein for treatment of disease in a vertebrate subject. The device can include a quasi-planar substrate; and one or more laterally-mobile effector molecule types at least partially embedded within the quasi-planar substrate, wherein the one or more laterally-mobile effector molecule types is configured to interact with one or more cell types. The device can further include one or more sensors configured to detect at least one aspect of an interaction between the at least one of the one or more laterally-mobile effector molecule types and the one or more cell types; and a controller in communication with the one or more sensors, wherein the controller is configured to responsively initiate modification of at least one of the one or more laterally-mobile effector molecule types, the quasi-planar substrate, and the one or more cell types.

2. 发明申请

US20170239413A1 DEVICE, SYSTEM, AND METHOD INCLUDING MICRO-PATTERNED CELL TREATMENT ARRAY 审中-公开
公开(公告)号：US20170239413A1
公开(公告)日：2017-08-24
申请号：US15493273
申请日：2017-04-21
申请人： Deep Science LLC
发明人： Roderick A. Hyde , Lowell L. Wood, Jr.
IPC分类号： A61M1/36 , G01N33/50 , C12Q3/00 , A61B17/435
CPC分类号： A61M1/3689 , A61B17/435 , B82Y20/00 , C12Q3/00 , G01N33/505 , G01N33/5091 , Y10T436/115831
摘要： Devices, systems, or methods are disclosed herein for treatment of disease in a vertebrate subject. The device can include a quasi-planar substrate; and one or more laterally-mobile effector molecule types at least partially embedded within the quasi-planar substrate, wherein the one or more laterally-mobile effector molecule types is configured to interact with one or more cell types. The device can further include one or more sensors configured to detect at least one aspect of an interaction between the at least one of the one or more laterally-mobile effector molecule types and the one or more cell types; and a controller in communication with the one or more sensors, wherein the controller is configured to responsively initiate modification of at least one of the one or more laterally-mobile effector molecule types, the quasi-planar substrate, and the one or more cell types.

3. 发明申请

US20170173254A1 DEVICES, SYSTEMS AND METHODS FOR CELL MODIFICATION 审中-公开
公开(公告)号：US20170173254A1
公开(公告)日：2017-06-22
申请号：US15453817
申请日：2017-03-08
申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education
发明人： WILLIAM J. FEDERSPIEL , JOHN ALSTON KELLUM , KAI SINGBARTL
IPC分类号： A61M1/36 , A61K35/15
CPC分类号： A61M1/3689 , A61K35/15 , A61K2035/124 , A61M1/3687
摘要： A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.

4. 发明授权

US09381292B2 Diabetes regulator 有权
标题翻译：糖尿病监管者
公开(公告)号：US09381292B2
公开(公告)日：2016-07-05
申请号：US14339984
申请日：2014-07-24
申请人： Kamal Ahmed Aljohani
发明人： Kamal Ahmed Aljohani
IPC分类号： A61M1/36 , A61K38/28 , A61K38/26 , A61M1/34 , A61K35/39
CPC分类号： A61M1/3689 , A61K35/39 , A61K38/26 , A61K38/28 , A61M1/34 , A61M1/3406 , A61M1/36 , A61M2205/04 , A61M2205/75 , A61M2230/201 , C12N5/0087 , C12N2510/02
摘要： An implantable device that continuously regulates the blood glucose levels of a type 1 diabetes mellitus patient is provided. The device which is implanted in the bloodstream, relies on a microfluidic chip and a microsieve that efficiently separate leukocytes away from an amount of blood received and an islet compartment made up of multiple islets (beta and alpha cells) from at least one compatible donor pancreas source. During hyperglycemia, insulin is produced by the beta cells to remove excessive sugar from the blood. Similarly, during hypoglycemia, glucagon is secreted by the alpha cells to bring the blood glucose level back to normal. The device is self-sustaining without relying on an electrically-powered insulin pump or refills of exogenous insulin.
摘要翻译：提供了连续调节1型糖尿病患者的血糖水平的可植入装置。植入血液中的装置依赖于微流体芯片和微量筛选器，其有效地将白细胞与接受的血液量分离开，以及由多个胰岛（β和α细胞）组成的胰岛室，其由至少一种相容的供体胰腺资源。在高血糖期间，β细胞产生胰岛素以从血液中除去过量的糖。类似地，在低血糖期间，胰高血糖素由α细胞分泌以使血糖水平恢复正常。该装置是自主维持的，而不依赖于电动胰岛素泵或补充外源性胰岛素。

5. 发明授权

US08758287B2 Utilization of stents for the treatment of blood borne carcinomas 有权
标题翻译：利用支架治疗血液癌
公开(公告)号：US08758287B2
公开(公告)日：2014-06-24
申请号：US13128870
申请日：2009-11-11
申请人： Mitchell S. Felder
发明人： Mitchell S. Felder
IPC分类号： A61M1/36 , A61M1/00
CPC分类号： A61M1/3687 , A61M1/3689
摘要： A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.
摘要翻译：过滤器和方法通过诱导癌细胞凋亡来治疗血液癌。过滤器包括支架，其具有限定包含填充材料和至少一种抗肿瘤剂的通道的内壁。该方法包括通过将血液泵送穿过支架来放置患者的血液与抗肿瘤剂的结合。血液保持与抗肿瘤药物相适应足够的时间以诱导凋亡级联。

6. 发明申请

US20130251672A1 METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2 AND IL2 IN PATIENTS 审中-公开
标题翻译：方法和系统去除可溶性TNFR1，TNFR2和IL2患者
公开(公告)号：US20130251672A1
公开(公告)日：2013-09-26
申请号：US13894963
申请日：2013-05-15
申请人： Biopheresis Technologies, Inc.
发明人： M. Rigdon LENTZ
IPC分类号： A61M1/34
CPC分类号： A61K39/3955 , A61F7/00 , A61K38/191 , A61K38/2013 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61M1/34 , A61M1/3406 , A61M1/3472 , A61M1/3482 , A61M1/3486 , A61M1/3489 , A61M1/3679 , A61M1/3689 , A61N5/10 , B01J20/00 , C07K14/525 , C07K14/55 , C07K16/2866 , C07K16/2878 , C07K17/00 , C07K2317/24 , C07K2317/622 , C07K2317/76
摘要： A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.
摘要翻译：已经开发了以sTNR和白细胞介素2过量产生为特征的疾病诱导缓解的方法和系统。在最优选的实施方案中，该系统由固定在含有诸如SEPHAROSE TM的材料的柱中的sTNFR1，sTNFR2和sIL2R的抗体组成。患者连接到将血液分离成血浆和红细胞的血液分离机，血浆循环通过柱直到达到期望的sTNFR1，sTNFR2和IL2水平的降低，优选达到小于正常水平。在优选的方法中，将患者每周治疗三次，持续四周。这个过程可以在一段时间后重复。临床研究表明，常规化疗和放射治疗失败的患者的肿瘤负荷减少。

7. 发明授权

US08206330B2 Device, system, and method for controllably reducing inflammatory mediators in a subject 有权
标题翻译：用于可控地减少受试者中的炎性介质的装置，系统和方法
公开(公告)号：US08206330B2
公开(公告)日：2012-06-26
申请号：US12455261
申请日：2009-05-28
申请人： Roderick A. Hyde , Muriel Y. Ishikawa , Edward K. Y. Jung , Robert Langer , Eric C. Leuthardt , Nathan P. Myhrvold , Elizabeth A. Sweeney , Lowell L. Wood, Jr.
发明人： Roderick A. Hyde , Muriel Y. Ishikawa , Edward K. Y. Jung , Robert Langer , Eric C. Leuthardt , Nathan P. Myhrvold , Elizabeth A. Sweeney , Lowell L. Wood, Jr.
IPC分类号： A61M37/00 , A61M31/00 , C02F1/44 , C02F1/00 , B01D39/00
CPC分类号： A61M1/30 , A61B18/042 , A61B18/1815 , A61B2018/1861 , A61M1/3679 , A61M1/3681 , A61M1/3683 , A61M1/3687 , A61M1/3689 , A61M5/14276 , A61M5/1723 , A61N5/02 , A61N5/062 , A61N7/02 , A61N2007/0039
摘要： Devices, systems, and methods are provided for controlling an inflammatory response in a subject. Extracorporeal devices, systems, and methods are provided that alter the functional structure of one or more inflammatory mediators in the peripheral blood of the subject. The device or system is useful in a method for treating an inflammatory disease or condition in the subject.
摘要翻译：提供了用于控制受试者的炎症反应的装置，系统和方法。提供体外装置，系统和方法，其改变受试者外周血中一种或多种炎症介质的功能结构。该装置或系统可用于治疗受试者的炎性疾病或病症的方法。

8. 发明申请

US20110251544A1 Utilization of Stents for the Treatment of Blood Borne Carcinomas 有权
标题翻译：利用支架治疗血液癌
公开(公告)号：US20110251544A1
公开(公告)日：2011-10-13
申请号：US13128870
申请日：2009-11-11
申请人： Mitchell S. Felder
发明人： Mitchell S. Felder
IPC分类号： A61M1/34
CPC分类号： A61M1/3687 , A61M1/3689
摘要： A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.
摘要翻译：过滤器和方法通过诱导癌细胞凋亡来治疗血液癌。过滤器包括支架，其具有限定包含填充材料和至少一种抗肿瘤剂的通道的内壁。该方法包括通过将血液泵送穿过支架来放置患者的血液与抗肿瘤剂的结合。血液保持与抗肿瘤药物相适应足够的时间以诱导凋亡级联。

9. 发明申请

US20110003359A1 BIODEVICE 审中-公开
公开(公告)号：US20110003359A1
公开(公告)日：2011-01-06
申请号：US12865837
申请日：2009-02-03
申请人： Yoichi Fujiyama , Yoichi Tagawa , Shunsuke Kobayashi
发明人： Yoichi Fujiyama , Yoichi Tagawa , Shunsuke Kobayashi
IPC分类号： C12N11/00
CPC分类号： C12M23/34 , A61M1/3689 , C12M25/02
摘要： Disclosed is a biodevice which has a porous membrane (8) and flow paths (10) and (12) formed therein. In a preferred embodiment, the flow path (10) and the flow path (12) are opposed to each other with the porous membrane (8) being interposed between them. The flow path (10) serves as a first reaction chamber through which a first solution is allowed to pass so as to be brought into contact with one of the surfaces of the porous membrane (8). The flow path (12) serves as a second reaction chamber through which a second solution is allowed to pass so as to be brought into contact with the other surface of the porous membrane (8). In the flow path (10), first cells are immobilized on the porous membrane (8). In the flow path (12), second cells are immobilized on the porous membrane (8).
摘要翻译：公开了一种生物装置，其具有形成在其中的多孔膜（8）和流路（10）和（12）。在优选实施例中，流动路径（10）和流动路径（12）彼此相对，多孔膜（8）插入在它们之间。流路（10）用作第一反应室，通过该第一反应室使第一溶液通过以与多孔膜（8）的一个表面接触。流路（12）用作第二反应室，通过该第二反应室使第二溶液通过以与多孔膜（8）的另一表面接触。在流路（10）中，将第一细胞固定在多孔膜（8）上。在流路（12）中，将第二细胞固定在多孔膜（8）上。

10. 发明申请

US20090081296A1 Extracorporeal cell-based therapeutic device and delivery system 审中-公开
标题翻译：体外细胞治疗装置和输送系统
公开(公告)号：US20090081296A1
公开(公告)日：2009-03-26
申请号：US12228895
申请日：2008-08-15
申请人： H. David Humes , Deborah Buffington , Gretchen Hageman
发明人： H. David Humes , Deborah Buffington , Gretchen Hageman
IPC分类号： A61K9/10 , A61K35/12 , C12N5/06 , A61M1/36
CPC分类号： A61M1/3653 , A61M1/1678 , A61M1/1696 , A61M1/1698 , A61M1/28 , A61M1/284 , A61M1/285 , A61M1/3687 , A61M1/3689 , A61M2202/09
摘要： Extracorporeal cell-based therapeutic devices and delivery systems are disclosed which provide a method for therapeutic delivery of biologically active molecules produced by living cells in response to a dynamic physiologic environment. One embodiment includes long hollow fibers in which a layer of cells are grown within the intraluminal volume or within a double hollow-filled chamber. Another embodiment includes a wafer or a series of wafers providing a substrate onto which cells are grown. The wafer(s) are inserted into a device. A device may deliver a pre-selected molecule, for example, a hormone, into a mammal's systemic circulation and/or may deliver a member of different cell products. The device is adapted to secure viable cells which produce and secrete the pre-selected molecule into blood or fluid. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel or body cavity the device of the invention.
摘要翻译：公开了基于体外细胞的治疗装置和递送系统，其提供了响应于动态生理环境而由活细胞产生的生物活性分子的治疗递送的方法。一个实施方案包括长的中空纤维，其中细胞层在腔内体积内生长或在双重中空填充的室内生长。另一个实施例包括晶片或一系列晶片，其提供生长细胞的基底。将晶片插入设备中。装置可以将预先选择的分子例如激素递送到哺乳动物的体循环中和/或递送不同细胞产物的成员。该装置适于将产生和分泌预先选择的分子的活细胞固定到血液或流体中。本发明还提供了一种用于经皮引入本发明的装置的预选血管或体腔的微创方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式